Teikoku Hormone Mfg. Co., Ltd.

Aska Pharmaceutical Co., Ltd.

Shigeki Iwashita

Naoyuki Koizumi

Shigehiro Takegawa

Mamoru Mieda

Hiroo Takahashi

Tomoko Kawachi

Hiroyuki Hayashi

Koichi Miyazaki

Kenyu Shibata

Takayoshi Nakagawa

Tomohito Fujii

Makoto Okada

Teruaki Matsui

Seijiro Honma

Kaoru Ueda

Koichi Minato

Mitsuteru Numazawa

Tomoyuki Saito

Fumiko Inoue

Provided is a crystalline polymorphic form A of 15&#x3b2;-hydroxy-osaterone acetate having an improved stability (storage stability, pulverization stability, and absorption characteristics). In a powder X-ray diffraction spectrum, characteristic diffraction peaks of the crystalline polymorphic form A of 15&#x3b2;-hydroxy-osaterone acetate appear at diffraction angles 2&#x3b8; of 9.6&#xb0;&#xb1;0.2&#xb0;, 17.1&#xb0;&#xb1;0.2&#xb0;, and 20.2&#xb0;&#xb1;0.2&#xb0;. The crystalline polymorphic form A has a melting point of 280 to 283&#xb0; C. and is a prism crystal.

Crystalline polymorph of 15B-hydroxy-osaterone acetate

A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by dissolving an isopropanol-solvated crystal of ulipristal acetate in a mixed solvent containing ethanol and water, and crystallizing an ulipristal acetate from the solution without addition of a seed crystal to the solution.

Crystalline polymorphic form of ulipristal acetate

A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by crystallization or transition in association with a specified solvent. The solvent comprises at least one member selected from the group consisting of water, an aliphatic hydrocarbon, an aromatic hydrocarbon, a halogenated hydrocarbon, a linear alcohol, an alkyl ether, an acetate ester, an alkyl ketone, an N-alkylacylamide, and an alkanenitrile.

This invention provides cyclicamino-phenyl sulfamate derivatives represented by a formula 

Growing community of inventors

Kanagawa, Japan

Shigeki Iwashita